Table 3.
Unconditional Logistic Regression of Serum and Plasma Hormones and Male Breast Cancer Risk
| Variable | Controls | Cases | OR* | 95% CI | P | Controls | Cases | OR† | 95% CI | P |
|---|---|---|---|---|---|---|---|---|---|---|
| Estradiol to testosterone ratio | ||||||||||
| < 0.004 | 55 | 21 | 1.00 | Referent | 50 | 16 | 1.00 | Referent | ||
| 0.004 to < 0.005 | 54 | 24 | 1.15 | 0.57 to 2.32 | .70 | 47 | 23 | 1.57 | 0.73 to 3.38 | .24 |
| 0.005 to < 0.007 | 53 | 24 | 1.19 | 0.58 to 2.45 | .64 | 50 | 23 | 1.45 | 0.66 to 3.16 | .36 |
| ≥ 0.007 | 54 | 32 | 1.57 | 0.78 to 3.13 | .20 | 52 | 30 | 1.95 | 0.90 to 4.24 | .09 |
| Continuous | 216 | 101 | 1.42 | 0.83 to 2.43 | .20 | 199 | 92 | 1.57 | 0.86 to 2.87 | .14 |
| Testosterone to DHT ratio | ||||||||||
| < 0.088 | 55 | 19 | 1.00 | Referent | 51 | 18 | 1.00 | Referent | ||
| 0.088 to < 0.105 | 53 | 34 | 1.82 | 0.92 to 3.61 | .08 | 52 | 32 | 1.73 | 0.85 to 3.50 | .13 |
| 0.105 to < 0.127 | 54 | 19 | 0.97 | 0.46 to 2.06 | .95 | 48 | 16 | 0.92 | 0.42 to 2.03 | .84 |
| ≥ 0.127 | 54 | 29 | 1.49 | 0.74 to 3.01 | .26 | 48 | 26 | 1.54 | 0.74 to 3.21 | .25 |
| Continuous | 216 | 101 | 0.89 | 0.55 to 1.43 | .62 | 199 | 92 | 0.92 | 0.57 to 1.50 | .74 |
| Estrone to androstenedione ratio | ||||||||||
| ≥ 0.025 | 53 | 20 | 1.00 | Referent | 47 | 17 | 1.00 | Referent | ||
| 0.025 to < 0.033 | 53 | 26 | 1.29 | 0.64 to 2.62 | .48 | 48 | 25 | 1.45 | 0.68 to 3.08 | .33 |
| 0.033 to < 0.042 | 53 | 22 | 1.09 | 0.51 to 2.32 | .82 | 48 | 19 | 1.06 | 0.47 to 2.38 | .89 |
| ≥ 0.042 | 52 | 32 | 1.67 | 0.79 to 3.56 | .18 | 51 | 31 | 1.70 | 0.75 to 3.82 | .20 |
| Continuous | 211 | 100 | 1.18 | 0.71 to 1.96 | .51 | 194 | 92 | 1.17 | 0.69 to 1.98 | .56 |
| Estradiol to estrone ratio | ||||||||||
| < 0.679 | 53 | 21 | 1.00 | Referent | 52 | 18 | 1.00 | Referent | ||
| 0.679 to < 0.818 | 53 | 28 | 1.35 | 0.68 to 2.70 | .39 | 46 | 25 | 1.61 | 0.77 to 3.35 | .20 |
| 0.818 to < 0.942 | 52 | 20 | 1.00 | 0.48 to 2.07 | .99 | 50 | 19 | 1.13 | 0.53 to 2.42 | .75 |
| ≥ 0.942 | 53 | 31 | 1.56 | 0.79 to 3.08 | .20 | 46 | 30 | 1.99 | 0.98 to 4.06 | .06 |
| Continuous | 211 | 100 | 1.49 | 0.75 to 2.97 | .26 | 194 | 92 | 1.92 | 0.89 to 4.17 | .10 |
| Sum of estrone plus estradiol | ||||||||||
| < 123.23 | 53 | 18 | 1.00 | Referent | 51 | 16 | 1.00 | Referent | ||
| 123.23 to < 153.58 | 53 | 18 | 0.98 | 0.45 to 2.11 | .96 | 46 | 17 | 1.14 | 0.51 to 2.56 | .74 |
| 153.58 to < 195.12 | 53 | 37 | 2.02 | 1.00 to 4.12 | .05 | 47 | 33 | 2.15 | 1.02 to 4.54 | .04 |
| ≥ 195.12 | 52 | 27 | 1.48 | 0.68 to 3.24 | .32 | 50 | 26 | 1.57 | 0.70 to 3.53 | .27 |
| Continuous | 211 | 100 | 1.40 | 0.78 to 2.51 | .26 | 194 | 92 | 1.38 | 0.76 to 2.51 | .29 |
| Estradiol to sum of ADT-G, 3α-diol-3G, 3α-diol-17G, and DHT ratio | ||||||||||
| < 0.0005 | 54 | 18 | 1.00 | Referent | 48 | 15 | 1.00 | Referent | ||
| 0.0005 to < 0.0008 | 54 | 20 | 1.17 | 0.55 to 2.49 | .69 | 49 | 18 | 1.18 | 0.53 to 2.66 | .68 |
| 0.0008 to < 0.0011 | 54 | 25 | 1.49 | 0.70 to 3.19 | .30 | 51 | 23 | 1.50 | 0.66 to 3.37 | .33 |
| ≥ 0.0011 | 52 | 36 | 2.34 | 1.05 to 5.20 | .04 | 49 | 34 | 2.27 | 0.98 to 5.29 | .06 |
| Continuous | 214 | 99 | 1.20 | 0.86 to 1.69 | .29 | 197 | 90 | 1.19 | 0.83 to 1.70 | .34 |
| Sum of estrone plus estradiol to sum of ADT-G, 3α-diol-3G, 3α-diol-17G, and DHT ratio | ||||||||||
| < 0.0011 | 53 | 15 | 1.00 | Referent | 47 | 12 | 1.00 | Referent | ||
| 0.0011 to < 0.0016 | 52 | 28 | 1.98 | 0.94 to 4.19 | .07 | 48 | 27 | 2.21 | 0.99 to 4.93 | .05 |
| 0.0016 to < 0.0023 | 53 | 21 | 1.43 | 0.64 to 3.23 | .39 | 48 | 19 | 1.51 | 0.63 to 3.65 | .35 |
| ≥ 0.0023 | 51 | 34 | 2.45 | 1.06 to 5.65 | .04 | 49 | 32 | 2.38 | 0.98 to 5.80 | .06 |
| Continuous | 209 | 98 | 1.09 | 0.78 to 1.51 | .62 | 192 | 90 | 1.05 | 0.75 to 1.47 | .76 |
Abbreviations: 3α-diol-3G, 3-androstanediol-3 glucuronide; 3α-diol-17G, 3-androstanediol-17 glucuronide; ADT-G, androsterone glucuronide; DHT, dihydrotestosterone; OR, odds ratio.
*
Adjusted for race, date at blood draw, and age at blood draw. Continuous sex steroid hormone values were standardized to half of difference between 75th and 25th centiles of distribution before correlative analysis.
†
Adjusted additionally for body mass index as continuous variable.